Zayo Group Appoints New CEO of Zayo Europe
Zayo Group, a leading global provider of network infrastructure, has appointed Colman Deegan as its new CEO of Zayo Europe to drive the business’ growth as cloud and AI adoption continues across the continent. This appointment is effective as of April 16, 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240419471253/en/
Colman Deegan, CEO Zayo Europe (Photo: Business Wire)
Steve Smith, CEO Zayo Group, says, “Colman’s experience and proven track record as a CEO leading large teams and businesses makes him perfectly equipped to take our European business to new heights, together with our outstanding local team. Colman will drive Zayo forward, strengthening our partnerships with data centres, hyperscalers, and enterprises across Europe. Under Colman’s leadership, we are confident that we will achieve our bold ambitions and maximise our impact in the European market.”
Deegan spent more than two decades at Vodafone where he held senior leadership positions such as Group M&A Director, CFO at Vodafone India and Italy as well as CEO of Vodafone Turkey. Most recently, as Vodafone Spain’s CEO, he led a successful operational turnaround in one of the most competitive markets.
Colman Deegan, CEO at Zayo Europe, says, “I am delighted to join Zayo Europe and lead this world-class team. Zayo is a leading player in the European market providing top-tier connectivity through its best-in-class fibre network. It’s an exciting time for the digital infrastructure sector given Zayo’s latest investments in Europe and the significant growth opportunities that lay ahead.”
About Zayo
For more than 15 years, Zayo has empowered some of the world’s largest and most innovative companies to connect what’s next for their business. Zayo’s future-ready network spans over 17.5 million fibre miles and 142,500 route miles. Zayo’s tailored connectivity and edge solutions enable carriers, cloud providers, data centres, schools, and enterprises to deliver exceptional experiences, from edge to core to cloud. Discover how Zayo connects what’s next at www.zayo.com and follow us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240419471253/en/
Contact information
Ben Rogers, Antidote Communications
zayogroup@antidotecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street Announces Fiscal First Quarter 2024 Financial and Operating Results2.5.2024 14:05:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced results for the fiscal first quarter ended March 31, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502994935/en/ Rimini Street Announces Fiscal First Quarter 2024 Financial and Operating Results (Graphic: Business Wire) Select First Quarter 2024 Financial Highlights Revenue was $106.7 million for the 2024 first quarter, an increase of 1.2% compared to $105.5 million for the same period last year. U.S. revenue was $53.8 million for the 2024 first quarter, an increase of 0.7% compared to $53.4 million for the same period last year. International revenue was $52.9 million for the 2024 first quarter, an increase of 1.6% compared to $52.1 million for the same period last year. Annuali
Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer2.5.2024 14:00:00 EEST | Press release
Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments. The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis. Mariana Oncology has developed a robust portfolio of novel peptide based-radiopharmaceuticals targeting a broad spectrum of solid tumor cancers, and has invested in manufacturing capabilities, an extensive isotope supply chain and novel formulations to enhance final product shelf-life. The company’s lead program, MC-339, is a novel radioligand therapy (RLT) designed to target small cell lung cancer. “Novartis is an established leader in the commercialization of radiopharmaceuticals with a world-class team and global reach. Together, we of
Lifezone Metals to Provide its Q1 2024 Operational Update and Financial Summary on Monday, May 13, 20242.5.2024 13:30:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) will release its operational update and unaudited financial summary for the first quarter of 2024 before market open on Monday, May 13, 2024. The company invites shareholders, investors, and members of the media to join the executive team for a virtual presentation and discussion of the Q1 summary and outlook. The presentation will be followed by a Q&A session where participants can engage directly with Lifezone’s senior management. Event details: Date: Monday, May 13, 2024. Time: 10:00 AM Eastern Time. Location: Virtual (please click the webcast registration link). The presentation slides will be available on Lifezone’s website on the day of the release. The webcast will be archived and accessible for replay for a limited time after the event. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Metals (NYSE: LZM), our mission is to provide cleaner and more responsible metals productio
Florin Filote joins ThredUp as General Manager of Europe2.5.2024 13:00:00 EEST | Press release
ThredUp (Nasdaq: TDUP, LTSE: TDUP), one of the largest online resale platforms for apparel, shoes, and accessories, today announced the appointment of Florin Filote as the company’s General Manager of Europe. With nearly two decades of experience in retail and ecommerce with an emphasis on building and scaling marketplace businesses, Filote will oversee the company’s European business operations, which currently span nine countries in Central and Eastern Europe. He succeeds Dan DeMeyere, who has been with ThredUp since 2010 and most recently ran the company’s international business for two years. DeMeyere is transitioning back to the U.S. business to scale technology and artificial intelligence innovation as Chief Product and Technology Officer. Filote and DeMeyere will both report to ThredUp CEO and Cofounder James Reinhart. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502300242/en/ Florin Filote, General Manager of Eu
Stallergenes Greer Publishes in the Lancet Regional Health-Europe Landmark EfficAPSI Real-world Study Confirming Significant Benefit of Its Liquid Sublingual AIT on the Onset and Progression of Allergic Asthma2.5.2024 11:23:00 EEST | Press release
Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that results of its EfficAPSI real-world study evaluating the impact of Stallergenes Greer liquid sublingual AIT (SLIT-liquid) on asthma onset and evolution in patients with allergic rhinitis have been published in the Lancet Regional Health-Europe. The publication is available online (https://doi.org/10.1016/j.lanepe.2024.100915) and will be available in print at a later date. This retrospective longitudinal pharmaco-epidemiological real-world study, which evaluated data over a 9-year period, included over 440,000 patients: more than 110,000 patients with allergic rhinitis, with or without asthma, treated with Stallergenes Greer SLIT-liquid and symptomatic drugs; compared to more than 330,000 patients with allergic rhinitis, with or without asthma, treated with symptomatic drugs only. The primary objective of the study was the evaluation of the real-world impact of Stallergene
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom